The company saw shares surge in October after sharing an update on lead drug candidate REQORSA to treat ALK-EML4 positive non-small cell lung cancer.
Genprex also completed a 1-for-50 reverse stock split in October.
The company has announced several updates early into 2026. On Jan. 7, Genprex provided a clinical update for GPX-002, the company's diabetes gene therapy drug candidate. The company reported positive preclinical data from studies for the candidate.
"This past year was instrumental for Genprex as we expanded our preclinical research beyond Type 1 diabetes and into Type 2 diabetes," Genprex CEO Ryan Confer said.
Confer said the company has requested a meeting with the FDA for Investigational New Drug studies, which could mark a "pivotal step toward human clinical trials."
For a small clinical-stage gene therapy company like Genprex, investors should be aware of high volatility as data is released and the company shares updates on its progress.
Genprex Stock Price Action
Genprex stock trades at $2.02 on Friday versus a 52-week trading range of $1.71 to $55.00. Genprex shares are down 94.8% over the last year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
